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Background: Obesity and obstructive sleep apnea (OSA) have been independently associated with increased risk of cardiovascular disease (CVD). 
Serum amyloid A (SAA), a major acute-phase protein released from the liver in response to inflammatory stimuli, has been proposed as a significant 
CVD risk factor. Obesity and OSA have both been implicated in increased SAA levels. However, since obesity and OSA often coexist, it is not clear 
whether obesity per se, in the absence of OSA, is associated with elevated SAA. The aim of the present study was to clarify whether SAA is increased 
in patients with elevated body mass index (BMI), without coexisting CVD and without OSA.
Methods: SAA levels were measured in 34 overweight and obese but otherwise healthy subjects without OSA (14 subjects with BMI 25-30 kg/m2 
and 20 subjects with BMI >30 kg/m2). SAA levels were also measured in 13 closely matched, normal healthy, OSA-free subjects with BMI <25 kg/
m2. All subjects had an overnight screening polysomnography to exclude occult OSA.
Results: SAA levels were similar among the three groups studied, BMI <25 kg/m2, BMI 25-30 kg/m2 and BMI >30 kg/m2 (11.4±3.3 vs. 13.3±3.2 
vs. 14.4±2.6 μg/mL respectively, P=0.78). There was no correlation between SAA levels and increasing BMI (r=0.16, P=0.3). Overall, the 34 
overweight and obese subjects had similar SAA levels as the 13 normal controls (14.0±2.0 vs. 11.4±3.3 μg/mL respectively, P=0.5). In subjects with 
BMI <25 kg/m2, SAA levels were not significantly different from those subjects with BMI >30 kg/m2 (11.4±3.3 vs. 14.4±2.6 μg/mL respectively, 
P=0.48). In this group of overweight and obese subjects who are otherwise healthy, and proven to be free of sleep apnea, levels of SAA were 
unaffected by body fat distribution, assessed as waist to hip ratio.
Conclusion: While obesity in and of itself may increase systemic inflammation, this is not associated with increased SAA. It suggests that SAA is not 
directly involved in the pathophysiology of metabolic and cardiovascular disease associated with obesity. It also suggests that prior data proposing 
that obesity causes increased SAA may be due to the presence of some other coexisting conditions, including undiagnosed OSA in obese individuals.
